Horizon Pharma (HZNP) Names Tina E. Ventura Vice President, Investor Relations

DUBLIN, IRELAND--(Marketwired - July 09, 2015) - Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today named Tina E. Ventura vice president, investor relations, reporting to John B. Thomas, executive vice president, strategy and investor relations, effective immediately.

"Tina is a skilled financial communicator with significant experience in the healthcare space," said John B. Thomas, executive vice president, strategy and investor relations, Horizon Pharma plc. "She will play an integral role in shaping the Horizon Pharma story for the investment community as we continue to grow the company at a rapid pace."

Ventura brings nearly two decades of investor relations and communications experience in the pharmaceutical, nutrition, diagnostic and medical device industries to Horizon. Most recently, Ventura was divisional vice president, investor relations at Abbott Laboratories where she was responsible for communicating the company's investment identity to Wall Street as well as maintaining close relationships with sell-side analysts and buy-side investors.

Ventura graduated from Northwestern University with a bachelor of science degree in communication. She also holds a master's degree in business administration from Loyola University.

About Horizon Pharma plc
Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.


Contacts:

Investors:
John Thomas
Executive Vice President, Strategy and Investor Relations
Email Contact

U.S. Media Contact:
Geoff Curtis
Group Vice President, Corporate Communications
Email Contact

Ireland Media Contact:
Ray Gordon
Gordon MRM

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.